101 Merritt 7, Ste 300,
Norwalk, CT 06851
Contact: Rhodemann Li, EVP Strategy & Finance – email@example.com
Vesselon is addressing a disease that will affect 1 in 6 adults during their lifetime – stroke. Our mission is to make a difference – to save the lives and quality of life for at least 1,000,000 stroke victims each and every year. We believe we are developing what will be akin to the world’s first automated external defibrillator (“AED”) for ischemic stroke. Distinct from all other therapies, our non-invasive solution aims to treat patients before or as they arrive at a hospital – critical because ‘time is brain.’ Just as AEDs now save cardiac arrest victims, we believe our immediate ischemic stroke treatment will save lives, improve outcomes and significantly reduce healthcare costs.
Our treatment uses two straightforward technologies to dissolve clots that cause ischemic stroke – noninvasive ultrasound and commercially available microbubbles – without tPA. Our fundamental approach is backed by $2 million in National Institutes of Health funded, related third-party research. In a peer reviewed meta-analysis of multiple clinical studies, the combination of ultrasound and microbubbles with tPA was found to be as safe as tPA alone, and more effective at opening blocked vessels earlier and more completely than tPA alone. In animal studies, ultrasound and microbubbles have been tested without tPA and have shown reduced infarct size and decreased intracerebral bleeding. We believe our solution will be the only AED-type device delivering highly automated treatment to a variety of stroke victims.